PROK | ProKidney Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.35 - 4.98
52 Week Range	3.95 - 14.19
Beta	1.58
Implied Volatility	280.00%
IV Rank	78.42%
Day's Volume	658,707
Average Volume	320,760
Shares Outstanding	419,404,029
Market Cap	1,975,392,977
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-30

Valuation
Profitability
Growth
Health
P/E Ratio	-8.72
Forward P/E Ratio	N/A
EPS	-0.54
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	87
Country	USA
Website	PROK

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK's peers: RLAY, STOK, PLRX, BDTX, ARVN, ACLX, VTYX, IMCR, PCVX, DICE, THRD, PMVP, EWTX, ENOB, RVMD, KURA, PTGX, MRUS, REPL, CERE, GLUE, ERAS, LYEL

*Chart delayed

Analyzing fundamentals for PROK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PROK Fundamentals page.

Watching at PROK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PROK Technicals page.